A Phase 2 Study of Prostate Specific Antigen Peptide 3A (PSA: 154-163(155L) ) (NSC 722932, IND 9787) With Montanide ISA-51(NSC 675756, IND 9787) or Montanide ISA 51 VG (NSC 737063) Vaccination in Prostate Cancer Recurrent
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Montanide ISA-51 (Primary) ; Prostate cancer vaccine (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 23 Jan 2013 Biomarkers information updated
- 20 Dec 2007 Status change from recruiting to completed
- 15 Oct 2007 Status changed from recruiting to in progress.